Drug Trial Radar · NCT07825025
The Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Apr 9, 2028
Study completion Apr 9, 2028
Sponsor
- Lead sponsor
- Zhongnan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.
Conditions
- Kidney Transplant
Interventions
HCA-N SolutionDrug
Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation
HTK SolutionDrug
control group using HTK Solution in kidney organ transplantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects experiencing delayed graft function (DGF) post-transplantation.Time frame: Baseline at Days 1, 3, 7, 14, and 28 post-transplantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.